A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
At a glance
Conditions
NCT05718570
Where you'd take part
This study runs at 55 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Advanced Rx Clinical Research
Westminster, Californiano site contact published
Anschutz Outpatient Pavilion
Aurora, Coloradono site contact published
APHM - HOPITAL DE LA CONCEPTION - Service d'endocrinologie, nutrition, diabète et obésité
Marseille, Franceno site contact published
APHP - LA PITIE SALPETRIERE_Service endrocrinologie et medecine de la reproduction
Paris, Franceno site contact published
Atlanta Diabetes Associates
Atlanta, Georgiano site contact published
Barrow Neurological Institute
Phoenix, Arizonano site contact published
Brigham & Women's Hospital
Boston, Massachusettsno site contact published
CHU LILLE - HOPITAL CLAUDE HURIEZ - Service d'endocrinologie et diabétologie
Lille, Franceno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Number of Adverse drug reaction (ADRs)From baseline (week 0) to end of study (between 1 week and a maximum of 10 years)
Measured as count of events.
- Incident NeoplasmFrom baseline (week 0) to end of study (between 1 week and a maximum of 10 years)
Measured as number of participants (yes/no).
- Incident Diabetes Mellitus type 2From baseline (week 0) to end of study (between 1 week and a maximum of 10 years)
Measured as number of participants (yes/no).